Zhengye Biotechnology Holding Limited - Class A Ordinary Shares (ZYBT)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — May 18, 2026Investment Snapshot
- Trading 18% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 2/9 — signs of financial weakness
- ROE of 4.0% — below-average profitability
- Revenue declining 35% annually
Zhengye Biotechnology Holding Limited - Class A Ordinary Shares (ZYBT) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $45 million . Key value metrics: P/E ratio 28.1, P/B ratio 0.94, Piotroski F-Score 2 out of 9 .
Value Score
Key Metrics
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Zhengye Biotechnology Holding Limited - Class A Ordinary Shares — Fundamental Analysis Summary
Zhengye Biotechnology Holding Limited - Class A Ordinary Shares (ZYBT) is currently trading 18% above its Graham Number of $0.81, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 28.1x.
On financial health, ZYBT shows a weak Piotroski F-Score of 2/9, a signal of deteriorating financial health, and modest return on equity of 4.0% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.04.
StockPik's composite Value Score for ZYBT is 44/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ZYBT reports a moderate gross margin of 20.5% (sector average: 40.1%) and a negative operating margin of -60.6%.
ZYBT shows revenue declining at 35% year-over-year, with earnings declining at 744%.